Last updated: April 10, 2025
Sponsor: Penn State University
Overall Status: Active - Recruiting
Phase
4
Condition
Aging
Menopause
Treatment
Estradiol patch
Elagolix Oral Tablet
placebo patch
Clinical Study ID
NCT06798571
Study 25435
Ages 42-64 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Women ages 42-64
Exclusion
Exclusion Criteria:
Chron's disease, diverticulitis, or similar gastrointestinal disease
Abnormal resting exercise electrocardiogram (ECG)
Tobacco use
High-risk determined by the Atherosclerotic Cardiovascular Disease (CVD) Risk Factor
Assessment
Using hormone therapy
Using hormonal contraceptives
Study Design
Total Participants: 24
Treatment Group(s): 4
Primary Treatment: Estradiol patch
Phase: 4
Study Start date:
March 01, 2025
Estimated Completion Date:
July 01, 2026
Study Description
Connect with a study center
Noll Laboratory
University Park, Pennsylvania 16802
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.